Description: Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.
Home Page: www.adimmune.com.tw
No. 3, Tanxing Road
Taichung,
427003
Taiwan
Phone:
886 4 2538 1220
Officers
| Name | Title |
|---|---|
| Mr. Chi-Hsien Chan | CEO & Chairman |
| Mr. Chung-Cheng Liu | Pres, GM & Director |
| Mr. Yin-Teng Chang | Chief Financial Officer |
| Mr. Chin-Chuan Chang | COO and VP of R&D |
| Ms. Li-Ya Tang | Director of Admin. Center |
| Mr. Fei Pan | Chief Legal Officer & Gen. Counsel |
| Dr. Chun Cheng Chen M.B.A., M.D., M.Sc., Ph.D. | Chief Medical Officer |
| Chih-Hsiang Leng | Head of R&D Division |
Exchange: TW
Country: TW
Currency: New Taiwan Dollar (NT$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 28.8115 |
| Price-to-Book MRQ: | 2.466 |
| Price-to-Sales TTM: | 6.1689 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |